Skip to main content
AVLN logo

AVLN · Avalyn Pharma Inc. · Financials

Track AVLN — free
$28.22 -0.48 (-1.67%)
Market Cap
$1.28B
Shares
44.52M
Volume · Nov 20 42.1K Avg daily vol (3M) 349.44K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Chart any reported metric, KPI or segment over time — the full statement history lives here

No structured figures reported for this view yet.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Long-term debt, including current maturities 2026-09-30 USD 14,817,000 10-Q filed 2026-11-12
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Line of credit borrowings, including current maturities
USD 15,000,000
Noncurrent debt carrying amount
USD 14,817,000
Operating lease liabilities 2026-09-30 USD 2,114,000 10-Q filed 2026-11-12
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 840,000
Noncurrent operating lease liabilities
USD 1,274,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 7.79×
EV/EBIT
—
Peer median 18.96×
P/E (TTM)
—
Peer median 11.77×
Price/Sales (TTM)
—
Peer median 9.80×
Price/Book
3.45×
Peer median 3.03×

Peer medians compare against the 287 similar-size Biotechnology companies (of 592 listed).

Valuation over time computed as of each quarter's filing date

Key facts CIK 1540171 CUSIP 05348Y105 13F (30d) 112 filings 110 filers Visit website Investor relations